IMTXImmatics N.V.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $8.64 · now $8.64 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IMTX has typically landed between $6.62 and $11.06 — a range of −23.4% to +28.0% from the issuance price $8.64.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,929 overlapping 1 month windows · 2018-12-122026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($8.64) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where IMTX has typically landed a month from the 2026-09-16 close of $8.64 — the range is history, not a prediction.

$6.62worst · -23.4%$11.06best · +28.0%
  • now $8.64 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.54 (-1.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $7.72$9.35
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.62$11.06
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,929 windows spanning 2018-12-12 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-06-26−40.4%−40.4%+0.0%
2020-06-22−36.9%−38.5%+0.0%
2023-09-29−36.4%−36.4%+0.0%
3 best
2025-09-10+87.6%−1.9%+87.6%
2025-09-16+80.5%+0.0%+81.7%
2025-09-09+79.1%−1.6%+79.1%

1,929 overlapping windows · 2018-12-122026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
25%
−6.8%
n=8
Feb
50%
−2.1%
n=8
Mar
38%
−4.6%
n=8
Apr
63%
+4.0%
n=8
May
75%
+9.2%
n=8
Jun
75%
+6.4%
n=8
Jul
63%
+2.1%
n=8
Aug
50%
−1.4%
n=8
Sep
50%
+6.2%
n=8
Oct
43%
−2.1%
n=7
Nov
43%
−2.3%
n=7
Dec
57%
+1.5%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$12$52026-08-26: 1 insider purchase, $7.5M — PERCEPTIVE ADVISORS LLC2026-08: 1 open-market purchase, $7.5M↑ buys↓ salesdirector PERCEPTIVE ADVISORS LLC — Purchase on 2026-08-26, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-08-26PERCEPTIVE ADVISORS LLCdirectorPurchase863,060 @ $8.69$7.5M+8.3% of holdingnot yet — horizon still opennot yet — horizon still open11,246,516Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

11 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-14Pepin James NelsonofficerAward / grant43,80043,800Form 4
2026-08-14Pepin James NelsonofficerAward / grant181,200181,200Form 4
2026-06-16Carter Paul RutherforddirectorAward / grant48,00048,000Form 4
2026-06-16Chambre Peter AlandirectorAward / grant48,00048,000Form 4
2026-06-16Forster EliotdirectorAward / grant48,00048,000Form 4
2026-06-16Hothum MathiasdirectorAward / grant48,00048,000Form 4
2026-06-16Mason Heather LdirectorAward / grant48,00048,000Form 4
2026-06-16REICIN ALISEdirectorAward / grant48,00048,000Form 4
2026-06-16Stone Adam LeodirectorAward / grant48,00048,000Form 4
2026-06-16PERCEPTIVE ADVISORS LLCdirectorAward / grant48,00048,000Form 4
2026-06-16ATIEH MICHAEL GdirectorAward / grant48,00048,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.